What Is Metoprolol (Lopressor / Toprol XL)? Uses, Side Effects & Warnings

Metoprolol is a beta-blocker — a class of drugs that reduces the effect of adrenaline (epinephrine) on the heart and blood vessels. It is one of the most commonly prescribed cardiovascular medications in the United States. Metoprolol comes in two formulations with separate brand names and different clinical applications: metoprolol tartrate (Lopressor), the immediate-release form, and metoprolol succinate (Toprol XL), the extended-release form. Understanding which formulation a patient is prescribed matters significantly, as they are not interchangeable without guidance.

What Metoprolol Is Used For

Metoprolol tartrate (IR) is FDA-approved for hypertension (high blood pressure), stable angina (chest pain from reduced blood flow to the heart), and reducing cardiovascular mortality after a heart attack (myocardial infarction).

Metoprolol succinate (ER) is approved for the same hypertension and angina indications, but additionally — and crucially — it is the only formulation of metoprolol approved for the treatment of stable heart failure with reduced ejection fraction. Clinical trials established that the extended-release formulation reduces mortality in heart failure, while the immediate-release form lacks this evidence base for that indication. Both formulations are also widely used off-label for rate control in atrial fibrillation, migraine prevention, essential tremor, performance anxiety, and hyperthyroidism symptoms.

How Metoprolol Works

Metoprolol selectively blocks beta-1 adrenergic receptors, which are concentrated in the heart. When beta-1 receptors are stimulated by adrenaline, the heart rate increases and the heart contracts more forcefully. By blocking this stimulation, metoprolol slows the heart rate, reduces the force of contraction, and decreases the workload placed on the heart. The combined effect lowers blood pressure, reduces oxygen demand (which explains its use in angina), and helps the failing heart function more efficiently over time.

The term "cardioselective" refers to metoprolol's preference for beta-1 receptors over beta-2 receptors. Beta-2 receptors are found in the airways and blood vessels. Non-selective beta-blockers (like propranolol) block both beta-1 and beta-2, which can cause airway constriction — making them problematic for people with asthma or COPD. Metoprolol's selectivity for beta-1 makes it safer for patients with mild-to-moderate respiratory disease, though the selectivity is not absolute and caution is still warranted.

Common Side Effects

• Fatigue and tiredness — very common; the reduced heart rate directly lowers exercise capacity for some
• Dizziness or lightheadedness
• Bradycardia (slow heart rate)
• Cold hands and feet — due to reduced peripheral blood flow
• Depression — beta-blockers have been associated with depressive symptoms; evidence is mixed
• Sexual dysfunction
• Sleep disturbances — vivid dreams or insomnia (more common with lipophilic beta-blockers like metoprolol)
• Shortness of breath — especially at high doses or in susceptible patients

Important Warnings

Metoprolol should be used with caution in patients with asthma, COPD, or other obstructive airway diseases, as even cardioselective beta-blockers can cause bronchospasm at higher doses or in sensitive patients. It is contraindicated in severe bradycardia, certain heart block conditions, and decompensated heart failure requiring intravenous inotropic agents.

In diabetic patients taking insulin or oral hypoglycemics, metoprolol can mask most of the sympathetic warning signs of hypoglycemia (low blood sugar), including rapid heart rate and palpitations. Sweating may still occur. Careful blood glucose monitoring is essential.

IR vs. ER: A Clinically Important Distinction

Metoprolol tartrate (IR/Lopressor) reaches peak blood levels quickly and must be taken twice daily to maintain consistent heart rate control. Metoprolol succinate (ER/Toprol XL) uses a polymer-based system to release drug steadily over 24 hours, allowing once-daily dosing and more stable blood levels. For heart failure specifically, only the succinate (ER) formulation has demonstrated mortality benefit in clinical trials. Extended-release tablets should not be crushed or chewed, as this destroys the controlled-release mechanism.

Key Drug Interactions

Combining metoprolol with other blood pressure medications, diuretics, or heart rate-slowing drugs (such as verapamil, diltiazem, digoxin, or amiodarone) can cause excessive bradycardia or low blood pressure. Fluoxetine and paroxetine (antidepressants) significantly inhibit CYP2D6, the enzyme that metabolizes metoprolol, and can raise metoprolol levels substantially. NSAIDs may blunt metoprolol's blood pressure-lowering effect. Clonidine and metoprolol together carry a risk of hypertensive rebound if clonidine is stopped first.

Frequently Asked Questions

Can you stop taking metoprolol suddenly?

No. Abruptly stopping metoprolol, especially in patients with coronary artery disease, can trigger a dangerous rebound effect including chest pain (angina) and, in serious cases, heart attack. Beta-blockers must always be tapered gradually under medical supervision. Never stop metoprolol on your own without talking to your doctor first.

What is the difference between metoprolol tartrate and metoprolol succinate?

Metoprolol tartrate (Lopressor) is the immediate-release form taken twice daily. Metoprolol succinate (Toprol XL) is the extended-release form taken once daily. Only the succinate formulation is FDA-approved for heart failure. They are not interchangeable on a milligram-for-milligram basis and should not be swapped without medical guidance.

Does metoprolol affect blood sugar in diabetics?

Yes. Beta-blockers can mask most warning signs of hypoglycemia — particularly rapid heartbeat and shakiness — because these are driven by the adrenaline surge the body produces in response to low blood sugar. Sweating is usually preserved. Diabetic patients on metoprolol should monitor blood glucose more carefully and inform all their treating providers they are on a beta-blocker.